Exclusive – India’s Lupin, U.S. firms weigh bids for GSK’s mature drugs: sources

Your Health Matters

An employee of Lupin Limited works at a reception at their headquarters in MumbaiBy Sophie Sassard and Zeba Siddiqui LONDON/MUMBAI (Reuters) – Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline (GSK) , five sources familiar with the matter said. Chief Executive Andrew Witty said in April GSK was reviewing its portfolio of mature drugs, known as established products, and in May the group invited sector players and private equity firms to consider bidding.

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave